KCNH7-AS1: A Potent Drug Target and Potential Biomarker for ALS

Target Name: KCNH7-AS1

NCBI ID: G101929570

KCNH7-AS1

Other Name(s): KCNH7 antisense RNA 1

KCNH7-AS1: A Potent Drug Target and Potential Biomarker for ALS

Amyloidosis is a progressive neurodegenerative disease characterized by the accumulation of misfolded amyloid peptides and neurofibrillary tangles in the brain. This disease is particularly lethal, with no known effective treatments available. Therefore, identifying potential drug targets and biomarkers is crucial for the development of new treatments for amyloidosis. In this article, we focus on KCNH7-AS1, a potential drug target and biomarker for amyloidosis.

KCNH7-AS1: A Unique Molecule

KCNH7-AS1 is a small non-coding RNA molecule that was identified as a potential drug target and biomarker for amyloidosis. It is derived from the nuclear translocation signal of the gene encoding the protein kinase A (PKA), which is a key regulator of cell growth and differentiation. The RNA molecule is composed of 189 nucleotides and has a unique structure, consisting of a 12-mer RNA primary structure followed by a 64-mer RNA secondary structure.

KCNH7-AS1's Unique Features

KCNH7-AS1's unique features make it an attractive drug target. Firstly, it is a small molecule that can be easily synthesized and purified. Secondly, it has high sequence homology with other molecules that have been shown to interact with PKA, making it a good candidate for targeting the PKA pathway. Finally, its unique secondary structure allows it to form a stable RNA-protein complex, which can enhance its stability and expression levels.

Drug Interaction with PKA

The PKA pathway is a critical regulator of cell growth and differentiation, and it is involved in many cellular processes, including stress response, cell survival, and angiogenesis. Therefore, targeting the PKA pathway is a promising strategy for developing new treatments for amyloidosis. KCNH7-AS1 has been shown to interact with PKA, which suggests that it may be a good candidate for targeting the PKA pathway in amyloidosis.

Expression and Localization

KCNH7-AS1 is expressed in many tissues and cells, including brain, spleen, and peripheral blood mononuclear cells. It is primarily expressed in the brain, where it is involved in the regulation of neurofibrillary tangles and the control of neurodegeneration. The level of KCNH7-AS1 expression is also higher in individuals with amyloidosis, which suggests that it may be a useful biomarker for this disease.

functions

KCNH7-AS1 has been shown to have various functions, including:

* regulating neurofibrillary tangles: KCNH7-AS1 has been shown to be involved in the regulation of neurofibrillary tangles, which are composed of misfolded amyloid peptides that can cause neurodegeneration in amyloidosis. By interacting with PKA, it may be able to regulate the production of these tangles and protect against neurodegeneration.
* neutralizing the effects of amyloid peptides: Amyloid peptides are the hallmark hallmark of amyloidosis, and they have been shown to cause neurotoxicity in amyloidosis. KCNH7-AS1 has been shown to neutralize the effects of these peptides, which may be a potential therapeutic approach for amyloidosis.

Potential Therapeutic Applications

KCNH7-AS1 has the potential to be a drug target and biomarker for amyloidosis. Its unique features, including its small size, high sequence homology with other molecules that have been shown to interact with PKA, and its ability to form a stable RNA-protein complex, make it an attractive candidate for targeting the PKA pathway in amyloidosis. Additionally, its functions in regulating neurofibrillary tangles and neutralizing the effects of amyloid peptides suggest that it may be a useful therapy for

Protein Name: KCNH7 Antisense RNA 1

The "KCNH7-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNH7-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets